0734 GMT - Novartis's 2025 guidance signals a slowdown in the growth outlook as patent expiries begin and pipeline catalysts are lacking, Berenberg analyst Kerry Holford says in a note. "In our view, Novartis is fully valued, pricing in a positive pipeline regeneration gap, which we struggle to support given its poor historical returns on R&D investment," she says. The Swiss pharma company will release a late-stage trial of its treatment for Sjogren's syndrome in the second half of the year, Holford says. However, more significant results are expected next year, such as the late-stage trial of cardiovascular disease prevention pelacarsen and thrombosis treatment abelacimab, the analyst says. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
March 17, 2025 03:34 ET (07:34 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.